Q-omics provides the consensus-scored NOS3 profile across patient tissues and cancer cell-line models. NOS3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NOS3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, NOS3 protein abundance shows 21,780 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, COAD, and PDAC as cancer lineages where NOS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOS3 survival associations across molecular data types. NOS3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOS3 RNA expression–survival associations across cancer types. High NOS3 expression shows unfavorable associations in KIRP, MESO, COAD, UVM and LGG, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NOS3 RNA expression.
This table summarizes NOS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NOS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOS3 shows lower tumor expression in KIRP, KICH and BLCA and higher tumor expression in COAD, HNSC and STAD. The COAD box plot shows higher NOS3 RNA expression in tumor versus normal tissue (log2 FC = +1.505, t-test p < 0.001).
This table shows molecular features associated with NOS3 in patient tissues and cancer cell lines. In patient samples, NOS3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
